Monte Rosa Therapeutics Inc (GLUE)
$5.54
+0.04
(+0.73%)▲
Insights on Monte Rosa Therapeutics Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 45.1% return, outperforming this stock by 48.9%
Performance
- $5.50$6.04$5.54
0.72%
Downside
Day's Volatility :8.94%
Upside
8.28%
- $2.44$8.84$5.54
55.96%
Downside
52 Weeks Volatility :72.4%
Upside
37.33%
Returns
| Period | Monte Rosa Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -1.96% | -0.4% | 0.0% |
6 Months | 107.55% | 9.6% | 0.0% |
1 Year | 7.63% | 3.9% | -1.3% |
3 Years | -71.55% | 12.8% | -22.1% |
Highlights
Market Capitalization | 293.4M |
Book Value | $3.58 |
Earnings Per Share (EPS) | -2.63 |
Wall Street Target Price | 16.83 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -27.72% |
Return On Equity TTM | -60.07% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -137.1M |
Diluted Eps TTM | -2.63 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.4 |
EPS Estimate Next Year | -2.26 |
EPS Estimate Current Quarter | -0.33 |
EPS Estimate Next Quarter | -0.64 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 203.79%
Technicals Summary
Sell
Neutral
Buy
Monte Rosa Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Monte Rosa Therapeutics Inc | -34.99% | 107.55% | 7.63% | -71.55% | -71.55% |
 Moderna, Inc. | -5.36% | 32.83% | -24.38% | -39.84% | 322.91% |
 Regeneron Pharmaceuticals, Inc. | -6.34% | 13.15% | 12.94% | 84.22% | 161.57% |
 Novo Nordisk A/s | -2.94% | 28.97% | 46.95% | 238.27% | 414.84% |
 Vertex Pharmaceuticals Incorporated | -3.87% | 8.77% | 20.15% | 83.53% | 128.04% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Monte Rosa Therapeutics Inc | 1.25 | NA | NA | -2.4 | -0.6 | -0.28 | NA | 3.58 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.77 | 25.77 | 1.46 | 45.22 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.13 | 46.13 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.39 | 28.39 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Monte Rosa Therapeutics Inc | Buy | $293.4M | -71.55% | 1.25 | 0.0% |
Moderna, Inc. | Buy | $38.8B | 322.91% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.4B | 161.57% | 25.77 | 30.14% |
Novo Nordisk A/s | Buy | $551.3B | 414.84% | 46.13 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 128.04% | 28.39 | 36.68% |
Institutional Holdings
NEA Management Company, LLC
15.34%FMR Inc
11.04%T. Rowe Price Associates, Inc.
9.85%Baker Bros Advisors LP
9.80%venBio Select Advisor LLC
9.04%BlackRock Inc
4.73%
Company Information
small molecule protein degraders are set to reshape the way by which diseases will be treated. our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. headquartered in boston with additional laboratory facilities in basel, monte rosa therapeutics is a private company launched in 2020. initially seeded by versant ventures and incubated at ridgeline discovery in basel, and the institute of cancer research in london, monte rosa has raised $32.5 million from versant and new enterprise associates. academic co-founders are prof. raj chopra and prof. ian collins of the institute for cancer research, uk.
Organization | Monte Rosa Therapeutics Inc |
Employees | 133 |
CEO | Dr. Markus Warmuth M.D. |
Industry | Services |
